Author

E. J. Moon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. J. Giaccia· 2 shared A. C. Koong· 1 shared A. Easton· 1 shared A. N. Diep· 1 shared B. Wei· 1 shared C. Beach· 1 shared C. Krieg· 1 shared D. Jiang· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. J. Giaccia

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Innate immune receptor C5aR1 regulates cancer cell fate and can be targeted to improve radiotherapy in tumours with immunosuppressive microenvironments

C. Beach, D. MacLean, D. Majorova, S. Melemenidis, D. K. Nambiar, R. K. Kim, G. N. Valbuena, S. Guglietta, C. Krieg, M. D. Damavandi, T. Suwa, A. Easton, E. Domingo, E. J. Moon, D. Jiang, , M. M. Olcina

This study identifies C5aR1 as a targetable receptor on cancer cells that enhances radiotherapy efficacy in immunosuppressive tumours by promoting apoptosis without affecting normal tissues.

bioRxiv · Jan 10, 2023 · PreprintCancer Biology

Neutralizing PD-L1 and PD-L2 Enhances the Efficacy of Immune Checkpoint Inhibitors in Ovarian Cancer.

Y. R. Miao, K. N. Thakkar, J. Qian, M. S. Kariolis, W. Huang, S. A. Nandagopal, T. Yang, A. N. Diep, G. M. Cherf, Y. Xu, E. J. Moon, Y. Xiao, H. Alemany, T. Li, W. Yu, , A. J. Giaccia

The paper develops a high-affinity sPD-1 decoy molecule that neutralizes both PD-L1 and PD-L2, showing superior antitumor activity in ovarian cancer models compared to PD-1/PD-L1 antibodies.

bioRxiv · Jan 19, 2020 · PreprintCancer Biology